Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis
Christine M. Bestvina(University of Chicago Medicine Comprehensive Cancer Center), Javier Baena(Research Institute Hospital 12 de Octubre), Valter Torri(Istituti di Ricovero e Cura a Carattere Scientifico), Floriana Morgillo(University of Campania "Luigi Vanvitelli"), Vieri Scotti(University of Florence), Giovanna Finocchiaro(Istituti di Ricovero e Cura a Carattere Scientifico), Juan Bautista Blaquier(Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno), Hirva Mamdani(Wayne State University), Céline Mascaux(Hôpitaux Universitaires de Strasbourg), Óscar Arrieta(Instituto Nacional de Cancerología), Heather A. Wakelee(Palo Alto Institute), Federica Grosso(Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo), Mary J. Fidler, Giannis Mountzios(Henry Dunant Hospital), Julien Mazières(Université Toulouse III - Paul Sabatier), Elisa Roca(Ospedale Versilia), Alessio Cortellini(Campus Bio Medico University Hospital), Leora Horn(Vanderbilt University), Solange Peters(University Hospital of Lausanne), Alfredo Addeo, Erica J. Geraedts(Groene Hart Ziekenhuis), Fred R. Hirsch(Tisch Hospital), Jennifer G. Whisenant(Vanderbilt-Ingram Cancer Center), Ardak Zhumagaliyeva(Semey Medical University), Alessandro De Toma(Fondazione IRCCS Istituto Nazionale dei Tumori), Balázs Halmos(Montefiore Medical Center), Avinash Aujayeb(Northumbria Healthcare NHS Foundation Trust), Carlo Genova(Ospedale Policlinico San Martino), Jacobo Rogado(Hospital Universitario Infanta Leonor), Marina Chiara Garassino(University of Chicago), Hina Khan, Jair Bar(Tel Aviv University), Anne-Cécile Métivier(Hôpital Foch), Carolyn J. Presley(The Ohio State University)
Cited by 18
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Lung cancer: current therapies and new targeted treatments
|The Lancet|2016|3.3k